What is Lakefront Biotherapeutics NV?
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 2.18B, and a P/E ratio of 2.4x.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.